TRCT
CDAK

Tower Research Capital (TRC)’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Tower Research Capital (TRC)’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,165
Closed -$1K – 6624
2023
Q1 		$1K Sell
7,165
-18,497
-72% -$10.3K ﹤0.01% 5732
2022
Q4 		$10K Buy
25,662
+19,089
+290% +$12.6K ﹤0.01% 4136
2022
Q3 		$5K Buy
6,573
+3,780
+135% +$7.93K ﹤0.01% 5204
2022
Q2 		$8K Buy
2,793
+1,168
+72% +$4.1K ﹤0.01% 4738
2022
Q1 		$10K Sell
1,625
-933
-36% -$5.86K ﹤0.01% 4401
2021
Q4 		$28K Buy
2,558
+1,952
+322% +$27.1K ﹤0.01% 3324
2021
Q3 		$10K Sell
606
-343
-36% -$6.14K ﹤0.01% 4378
2021
Q2 		$18K Buy
949
+77
+9% +$1.48K ﹤0.01% 4019
2021
Q1 		$13K Buy
872
+339
+64% +$7.37K ﹤0.01% 4232
2020
Q4 		$17K Buy
+533
New +$7.05K ﹤0.01% 3988

Tower Research Capital (TRC)'s CDAK Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 7,165 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $28K in Q4 2021. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Tower Research Capital (TRC) reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7,165 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Codiak BioSciences, Inc. Common Stock position peaked at $28K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.